MedTrace Logo

MicroRNA as Markers in Testicular Cancer

NCT04914026 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 350

Last updated 2022-08-08

No results posted yet for this study

Summary

The main objective of this study is establish the performance of miR371 in management of testicular cancer

Conditions

  • Testicular Germ Cell Cancer
  • Seminoma
  • Non-Seminoma Testicular Cancer
  • Stage I Testicular Cancer
  • Stage II Testicular Cancer
  • Stage III Testicular Cancer
  • Stage IV Testicular Cancer
  • Relapse Testicular Cancer

Interventions

OTHER

Biomarker analysis

Blood collection. Blood samples will be collected at diagnosis, during surveillance, during treatment and every 3-6 months

Sponsors & Collaborators

  • Karolinska University Hospital

    collaborator OTHER

  • Sahlgrenska University Hospital

    collaborator OTHER

  • Helse Fonna

    collaborator OTHER

  • University Hospital of North Norway

    collaborator OTHER

  • Oslo University Hospital

    collaborator OTHER

  • Haukeland University Hospital

    lead OTHER

Principal Investigators

  • Mette Pernille Myklebust, PhD · Haukeland University Hospital

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-31
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • Norway
  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04914026 on ClinicalTrials.gov